BlossomHill Therapeutics (BLSM) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($527.9 million vs $511.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | EOLS |
|---|---|---|
| Share price | $16.61 | $7.74 |
| Market cap | $527.95M | $511.23M |
| 1-day change | -3.93% | +4.88% |
| YTD return | — | +16.39% |
| 1-year return | — | +23.64% |
| 5-year return | — | +0.91% |
| Forward P/E | — | 26.46 |
| EPS (TTM) | $-4.51 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $9.31 |
| 52-week low | $15.25 | $3.86 |
| Distance from 52-week high | -40.66% | -16.86% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +113.12% | +93.80% |
| Average volume | 263.69K | 901.46K |
| Shares outstanding | 31.78M | 66.05M |
| Employees | 69 | 353 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Healthcare · Biotechnology · 69 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
BLSM vs EOLS FAQ
Which is bigger, BlossomHill Therapeutics or Evolus?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $527.95M compared with $511.23M for Evolus (EOLS).
Are BlossomHill Therapeutics and Evolus in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for BlossomHill Therapeutics and Drug Manufacturers - Specialty & Generic for Evolus.